At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,179 enrolled
Drug / intervention
Guaifenesin +1 moredrug
Likely dose
Guaifenesin 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Mucinex D for Symptomatic Therapy in Patients With Acute Upper Respiratory Tract Who Seek Treatment
In Brief
A Phase 4 clinical trial evaluating Guaifenesin and Placebo for Acute Upper Respiratory Track Infection. Completed, enrolled 1,179 participants across 24 sites.
Detailed Summary
The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Upper Respiratory Track Infection
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
Primary CompletionApr 2010
Study CompletionJul 2010
First PostedSep 2010
TodayJul 2026
First PostedSep 15, 2010
Enrollment StartOct 1, 2009
Primary CompletionApr 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.8 years ago
Interventions
Guaifenesindrug
1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
Placebodevice
Placebo bid for 7 days